The Latest Breaking News from Moderna

The youngest Americans could soon be inoculated against Covid, but whether uptake will help stoke vaccine stocks remains to be seen.

Partners Pfizer, Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) urged the FDA to authorize three vaccine doses for children below five, the Wall Street Journal reports. The companies previously asserted that three doses of the shot were 80% effective at preventing symptomatic Covid-19 with robust immune response in children between six months to five years. After mixed results…

A study in Japan found that women were significantly more likely than men to develop rash-like side effects after a first dose of Moderna Inc's COVID-19 vaccine.

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Pfizer’s COVID-19 vaccine became available for children aged five to 11 in the UK in April 2022. Those aged 12 and up had already been eligible since 2021.

Here are a few general tips for a safer and enjoyable holiday, and a quick look at the COVID situation in four popular holiday destinations.

Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted to the global Covax program following its approval by the WHO The approval could have limited benefits for the company as the pandemic fades and other products are widely available By Jony Ho

COVID-19 case numbers are rising again in the U.S. – including among children. In mid-May 2022, the Food and Drug Administration authorized a booster shot of the COVID-19 vaccine for U.S. children ages 5 to 11, and the Centers for Disease Control and Prevention followed by recommending a booster shot…

The annual Time 100 Most Influential People list for 2022 contains names such as U.S. President Joe Biden, Ukrainian President Volodymyr Zelenskyy and Chinese President Xi Jinping. The list also has several CEOs and names connected to public companies.

Moderna Inc is testing potential vaccines against monkeypox in pre-clinical trials as the disease spreads in the United States and Europe. The World Health Organization said on Tuesday there have been 131 confirmed monkeypox cases and 106 further suspected cases since the first was reported on May 7 outside the…

Moderna's (NASDAQ:MRNA) short percent of float has fallen 3.7% since its last report. The company recently reported that it has 15.43 million shares sold short, which is 4.43% of all regular shares that are available for trading.